Sort by
Previous Page Page 2 of 11 Next Page
  1. Research

    The economic burden of childhood pneumococcal diseases in The Gambia

    Streptococcus pneumoniae is a common cause of child death. However, the economic burden of pneumococcal disease in low-income countries is poorly described. We aimed to estimate from a...

    Effua Usuf, Grant Mackenzie, Sana Sambou, Deborah Atherly and Chutima Suraratdecha

    Cost Effectiveness and Resource Allocation 2016 14:4

    Published on: 17 February 2016

  2. Review

    Economic evaluations of interventions to reduce neonatal morbidity and mortality: a review of the evidence in LMICs and its implications for South Africa

    Newborn mortality, comprising a third of all under-5 deaths, has hardly changed in low and middle income countries (LMICs) including South Africa over the past decade. To attain the MDG 4 target, greater empha...

    Mandy Maredza, Lumbwe Chola and Karen Hofman

    Cost Effectiveness and Resource Allocation 2016 14:2

    Published on: 26 January 2016

  3. Research

    Efficiency of private and public primary health facilities accredited by the National Health Insurance Authority in Ghana

    Despite improvements in a number of health outcome indicators partly due to the National Health Insurance Scheme (NHIS), Ghana is unlikely to attain all its health-related millennium development goals before t...

    Robert Kaba Alhassan, Edward Nketiah-Amponsah, James Akazili, Nicole Spieker, Daniel Kojo Arhinful and Tobias F Rinke de Wit

    Cost Effectiveness and Resource Allocation 2015 13:23

    Published on: 26 December 2015

  4. Research

    Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

    The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific economic model based on a chronic obstructive pulmona...

    Yogesh Suresh Punekar, Graeme Roberts, Afisi Ismaila and Martin O’Leary

    Cost Effectiveness and Resource Allocation 2015 13:22

    Published on: 12 December 2015

  5. Research

    Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

    All international guidelines suggested that Tenofovir and Entecavir are the primary drugs at the first line therapy for the treatment of chronic hepatitis B (CHB). However, in Turkey these medications reimburs...

    Guvenc Kockaya, Akin Kose, Fatma Betul Yenilmez, Oktay Ozdemir and Ece Kucuksayrac

    Cost Effectiveness and Resource Allocation 2015 13:21

    Published on: 10 December 2015

  6. Research

    Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods

    In the Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST elevation myocardial infarction (FAMOUS) clinical trial, FFR was shown to significantly reduce coro...

    Julian Nam, Andrew Briggs, Jamie Layland, Keith G. Oldroyd, Nick Curzen, Arvind Sood, Kanarath Balachandran, Raj Das, Shahid Junejo, Hany Eteiba, Mark C. Petrie, Mitchell Lindsay, Stuart Watkins, Simon Corbett, Brian O’Rourke, Anna O’Donnell…

    Cost Effectiveness and Resource Allocation 2015 13:19

    Published on: 14 November 2015

  7. Research

    Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study

    Sequential treatment of ankylosing spondylitis (AS) that includes tumour necrosis factor-α antagonists (anti-TNF agents) has been applied in most of the Western countries. Existing cost-effectiveness (CE) mode...

    An Tran-Duy, Annelies Boonen, Mart A. F. J. van de Laar and Johan L. Severens

    Cost Effectiveness and Resource Allocation 2015 13:18

    Published on: 7 October 2015

  8. Research

    New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison

    In the US, the prevalence of hepatitis C virus (HCV) has surpassed the prevalence of human immunodeficiency virus (HIV), with about 3.3 million people chronically infected with the disease. Given the aging of ...

    Jennifer M. Poonsapaya, Michael Einodshofer, Heather S. Kirkham, Pheophilus Glover and Janeen DuChane

    Cost Effectiveness and Resource Allocation 2015 13:17

    Published on: 6 October 2015

  9. Research

    Matching comprehensive health insurance reimbursements to their real costs: the case of antenatal care visits in a region of Peru

    Prepaid contributory systems are increasingly being recognized as key mechanisms in achieving universal health coverage in low and middle-income countries. Peru created the Seguro Integral de Salud (SIS) to in...

    Daniel Cobos Muñoz, Kristian Schultz Hansen, Fern Terris-Prestholt, Fiona Cianci, José Enrique Pérez-Lu, Aldo Lama and Patricia J. García

    Cost Effectiveness and Resource Allocation 2015 13:16

    Published on: 19 September 2015

  10. Research

    Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy

    After implementation of the PREDICA annual chest X-ray (CXR) screening program in smokers in the general practice setting of Varese-Italy a significant reduction in lung cancer-specific mortality (18 %) was ob...

    Paolo Pertile, Albino Poli, Lorenzo Dominioni, Nicola Rotolo, Elisa Nardecchia, Massimo Castiglioni, Massimo Paolucci, William Mantovani and Andrea Imperatori

    Cost Effectiveness and Resource Allocation 2015 13:15

    Published on: 12 September 2015

  11. Research

    Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden

    Tiotropium (TIO) is a well-established bronchodilator, LAMA (long-acting anticholinergic), for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD). Clinical evidence suggests ...

    Oskar Eklund, Faraz Afzal and Fredrik Borgström

    Cost Effectiveness and Resource Allocation 2015 13:13

    Published on: 19 August 2015

  12. Research

    Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model

    For end-users of diabetes models that include UKPDS 82 risk equations, an important question is how well these new equations perform. Consequently, the principal objective of this study was to validate the UKP...

    Philip McEwan, Thomas Ward, Hayley Bennett and Klas Bergenheim

    Cost Effectiveness and Resource Allocation 2015 13:12

    Published on: 4 August 2015

  13. Research

    Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components

    The aim of this study was to compare the cost-utility of the first available single-pill triple combination antihypertensive therapy containing valsartan (V), amlodipine (A) and hydrochlorothiazide (H), with e...

    Panagiotis Stafylas, Georgia Kourlaba, Magda Hatzikou, Dimitrios Georgiopoulos, Pantelis Sarafidis and Nikolaos Maniadakis

    Cost Effectiveness and Resource Allocation 2015 13:10

    Published on: 9 June 2015

  14. Research

    Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

    Certolizumab pegol, a PEGylated tumour necrosis factor (TNF)-inhibitor, improves the clinical signs and symptoms of rheumatoid arthritis (RA) when used in combination with methotrexate or as monotherapy. This ...

    Álvaro Hidalgo-Vega, Renata Villoro, Juan Antonio Blasco, Pablo Talavera, Belén Ferro and Oana Purcaru

    Cost Effectiveness and Resource Allocation 2015 13:11

    Published on: 9 June 2015

  15. Research

    Cost-effectiveness of live oral attenuated human rotavirus vaccine in Tanzania

    Globally, diarrhoea is the second leading cause of morbidity and mortality, responsible for the annual loss of about 10% of the total global childhood disease burden. In Tanzania, Rotavirus infection is the ma...

    George M Ruhago, Frida N Ngalesoni, Bjarne Robberstad and Ole F Norheim

    Cost Effectiveness and Resource Allocation 2015 13:7

    Published on: 28 April 2015

  16. Research

    The determinants of technical efficiency of a large scale HIV prevention project: application of the DEA double bootstrap using panel data from the Indian Avahan

    In 2004, the largest HIV prevention project (Avahan) conducted globally was implemented in India. Avahan was implemented by NGOs supported by state lead partners in order to provide HIV prevention services to ...

    Aurélia Lépine, Anna Vassall and Sudhashree Chandrashekar

    Cost Effectiveness and Resource Allocation 2015 13:5

    Published on: 29 March 2015

  17. Research

    Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females

    The purpose of this study was to assess the consequences of a national immunization program with HPV vaccine for both boys and girls in Denmark, including the prophylactic effects on all potentially vaccine pr...

    Jens Olsen and Tine Rikke Jørgensen

    Cost Effectiveness and Resource Allocation 2015 13:4

    Published on: 11 February 2015

  18. Research

    Cost-effectiveness of using a social franchise network to increase uptake of oral rehydration salts and zinc for childhood diarrhea in rural Myanmar

    This paper examines the cost-effectiveness of achieving increases in the use of oral rehydration solution and zinc supplementation in the management of acute diarrhea in children under 5 years through social f...

    David Bishai, Karampreet Sachathep, Amnesty LeFevre, Hnin New Nwe Thant, Min Zaw, Tin Aung, Willi McFarland and Dominic Montagu

    Cost Effectiveness and Resource Allocation 2015 13:3

    Published on: 5 February 2015

Previous Page Page 2 of 11 Next Page